CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B…
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…
"Federal Marijuana Reform Is Coming-But FDA-Ready Companies Will Benefit the most" Duane Boise CEO MMJ…
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in…
NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Originally published on Bristol Myers…
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…